Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business

Heidelberg Pharma AG has released its financial report for the first half of 2024. The report highlights significant milestones, including preliminary efficacy data from the HDP-101 clinical trial in multiple myeloma, presentation of data at the AACR Meeting 2024, and FDA orphan drug designation for HDP-101.

The clinical trial for HDP-101 showed promising preliminary results, with three patients from the fifth cohort exhibiting partial remission. Additionally, Heidelberg Pharma sold future royalties of TLX250-CDx to HealthCare Royalty, securing a non-refundable upfront payment of USD 25 million.

Financially, the company reported a 34% revenue increase compared to the same period last year, amounting to EUR 6.3 million. Operating expenses decreased from EUR 20.7 million to EUR 15.6 million, leading to a reduced net loss of EUR 8.7 million from the previous year’s EUR 16.0 million.

Professor Andreas Pahl, recently appointed CEO, expressed optimism for patient recruitment and the continued positive development of clinical trials in the second half of 2024.